BioSpace

Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business

With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.

By BioSpace

1 min read
Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights